Montreal, Canada. July 9, 2012 – MethylGene Inc. (TSX:MYG) today announced that Mr. Charles Grubsztajn, President and Chief Executive Officer, will present an overview of the Company at the Seventh Annual JMP Securities Healthcare Conference which will be held at The Peninsula New York Hotel, New York City. Mr. Grubsztajn will present at 1:30 p.m. ET on Friday July 13, 2012. The JMP Securities Healthcare Conference is an institutional investor forum featuring more than 100 publicly traded and privately held companies in the life sciences sector. The presentation will be webcast live and available after the event on the Company’s website at www.methylgene.com.
MethylGene Inc. (TSX:MYG) is a small molecule drug development company that is advancing two novel therapeutics for cancer and infectious disease in human clinical trials. The Company’s lead product candidates are: MGCD290, an oral antifungal agent targeting the fungal Hos2 enzyme that is currently in Phase II trials for vulvovaginal candidiasis, and MGCD265, an oral Met/VEGF receptor kinase inhibitor that is in Phase I/II clinical trials for solid tumor cancers. MethylGene owns all rights to its lead product candidates, and has partnerships with Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and EnVivo Pharmaceuticals, Inc. for its other pipeline programs.
Investor Relations Contact:
Joseph Walewicz, CFA
Vice President, Business & Corporate Development
Phone: 514-337-3333 ext. 373
The Trout Group LLC